Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ROCO:4194's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 60.91 * Ranked among companies with meaningful Gross Margin % only.
Holy Stone Healthcare Co had a gross margin of N/A% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
Holy Stone Healthcare Co (ROCO:4194) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Holy Stone Healthcare Co had a gross margin of N/A% for the quarter that ended in Dec. 2025 => No sustainable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Holy Stone Healthcare Co Gross Margin % Related Terms
Holy Stone Healthcare Co Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:4194 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Holy Stone Healthcare Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Holy Stone Healthcare Co Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Holy Stone Healthcare Co's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Holy Stone Healthcare Co's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Holy Stone Healthcare Co (ROCO:4194) has a Gross Margin % of 0.00% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Holy Stone Healthcare Co and its competitors. Over the past decade, Holy Stone Healthcare Co's Gross Margin % has ranged from 27.67 to 57.79. According to the industry distribution chart, Holy Stone Healthcare Co ranks #999999 out of 733 companies in the Biotechnology industry.
Is Holy Stone Healthcare Co's Gross Margin % too high?
Holy Stone Healthcare Co's current Gross Margin % is 0.00%. Over the past 10 years, this metric has ranged from a low of 27.67 to a high of 57.79. Based on the distribution chart, Holy Stone Healthcare Co ranks #999999 out of 733 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Holy Stone Healthcare Co has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Holy Stone Healthcare Co's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Holy Stone Healthcare Co ranks #999999 out of 733 companies for Gross Margin %. This places Holy Stone Healthcare Co in the lower half of its industry. The industry median Gross Margin % is 60.91. Historically, Holy Stone Healthcare Co's own Gross Margin % has ranged from 27.67 to 57.79 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 733 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Holy Stone Healthcare Co and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Holy Stone Healthcare Co's current Gross Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Holy Stone Healthcare Co stock overvalued right now?
Based on GuruFocus' analysis, Holy Stone Healthcare Co (ROCO:4194) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$3.93, compared to a current price of NT$6.89 — trading 75.3% above its estimated fair value. The current Gross Margin % is 0.00%. Holy Stone Healthcare Co's overall GF Score™ is 45/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Holy Stone Healthcare Co (ROCO:4194), the current Gross Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Holy Stone Healthcare Co (ROCO:4194) Overvalued in 2026?
Based on GuruFocus' analysis, Holy Stone Healthcare Co stock appears to be overvalued.
The current stock price of NT$6.89 is trading 75.3% above its estimated GF Value™ of NT$3.93.
GuruFocus considers Holy Stone Healthcare Co to be Significantly Overvalued.
Key valuation signals for ROCO:4194:
Gross Margin %: 0.00%
GF Value™: NT$3.93 vs. price of NT$6.89 (75.3% above fair value)
No single metric tells the full story. See the ROCO:4194 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Holy Stone Healthcare Co Ltd is a Taiwan based company focused on a biopolymer drug delivery platform. It is involved in the development of new drugs and medical devices, especially hyaluronic acid related therapeutic products. The products of the company include RenehaVis, SportVis, TRUD, and GAF.
45GF Score
Get the complete analysis for ROCO:4194
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4194 has been successfully added to your 
